SCHEMBL27240259

SCHEMBL27240259

Cc1cc(C#Cc2ccccc2)cc(F)c1NC(=O)c1cc(NC(=O)OC(C)(C)C)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 2/20 0.38
▸ LCK P06239 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ PPARG P37231 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ NR1H4 Q96RI1 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ RORC P51449 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27240040 0.94 GRM5 (0.41) GRM5RXFP1PPARGPPARANR1H4
SCHEMBL23287980 0.89 NPC1 (0.39) GRM5PPARGPPARANR1H4SMN1; SMN2
SCHEMBL27240244 0.85 GRM5 (0.42) GRM5LCKRXFP1PPARGPPARA
SCHEMBL27240067 0.84 LCK (0.41) GRM5LCKPPARGPPARANR1H4
SCHEMBL29827331 0.83 GRM5 (0.42) GRM5RXFP1PPARGPPARANR1H4
SCHEMBL23273849 0.83 GRM5 (0.42) GRM5RXFP1PPARGPPARANR1H4
SCHEMBL23287990 0.82 MEN1 (0.39) GRM5PPARGPPARANR1H4SMN1; SMN2
SCHEMBL27240052 0.79 GRM5 (0.44) GRM5LCK
SCHEMBL23288019 0.79 RXFP1 (0.42) GRM5LCKRXFP1SMN1; SMN2KMT2A
SCHEMBL23287978 0.78 PPARG (0.38) GRM5PPARGSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190824-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION ONO PHARMACEUTICAL CO., LTD. (JP) 2024-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190824-A1 INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION KCNJ11, KCNJ1, KCNJ2 GRM5 1270/4885LCK 1917/4885RXFP1 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback